The impact of low advanced glycation end products diet on obesity and related hormones: a systematic review and meta-analysis by Sohouli, M.H. et al.
1
Vol.:(0123456789)
Scientific Reports |        (2020) 10:22194  | https://doi.org/10.1038/s41598-020-79216-y
www.nature.com/scientificreports
The impact of low advanced 
glycation end products 
diet on obesity and related 
hormones: a systematic review 
and meta‑analysis
Mohammad Hassan Sohouli1,2, Elham Sharifi‑Zahabi1,2, Abolfazl Lari1,2, Somaye Fatahi1,2 & 
Farzad Shidfar1,3*
Several randomized clinical trials (RCTs) have investigated the effect of dietary advanced glycation 
end products (AGE) on obesity factors and related hormones in adults; results were conflicting. 
Therefore, a study was performed to assess the effect of low advanced glycation end products diet on 
obesity and related hormones. A comprehensive literature search without any limitation on language 
was conducted using the following bibliographical databases: Web of Science, Scopus, Ovid MEDLINE, 
Cochrane, and Embase up to October, 2019. From the eligible trials, 13 articles were selected for 
the systematic review and meta‑analysis. Our systematic reviews and meta‑analyses have shown a 
significant decrease in BMI (WMD: − 0.3 kg/m2; 95% CI: − 0.52, − 0.09, p = 0.005;  I2 = 55.8%), weight 
(WMD: − 0.83 kg; 95% CI: − 1.55, − 0.10, p = 0.026;  I2 = 67.0%), and leptin (WMD: − 19.85 ng/ml; 95% 
CI: − 29.88, − 9.82, p < 0.001;  I2 = 81.8%) and an increase in adiponectin (WMD: 5.50 µg/ml; 95% CI: 
1.33, 9.67, p = 0.010;  I2 = 90.6%) levels after consumption of the low AGE diets compared to the high 
AGE diets. Also, the effect of intake of low AGE compared to high AGE diets was more pronounced in 
subgroup with duration > 8 weeks for the BMI and weight. Overall, according to our results, although 
low AGE diets appeared to be statistically significant in reducing the prevalence of obesity and chronic 
diseases compared to high consumption of dietary AGEs. But, no clinical significance was observed. 
Therefore, to confirm these results clinically, further prospective studies should be conducted in this 
regard. The study protocol was registered in the in International prospective register of systematic 
reviews (PROSPERO) database as CRD42020203734.
Overeating and concomitant obesity is a serious public health problem worldwide with close links to chronic 
health conditions such as diabetes mellitus and cardiovascular  diseases1. Obesity is associated with Inflammation 
and oxidative stress, which in turn lead to the genesis of non-communicable chronic  diseases2,3. Lifestyle modi-
fication, with a special focus on dietary pattern, plays an important role in the prevention and control of obesity 
and its related complication. Recent studies have demonstrated that the consumption of highly processed foods 
that are extremely high in fat, sugar, salt and potentially toxic compounds known as advanced glycation end-
products (AGEs)4,5 are associated with increased risk of chronic  diseases6,7. AGEs are a group of sugar modifica-
tions which are formed through the non-enzymatic reaction of sugars with free amino groups of proteins, lipids 
or nucleic  acids5,8. AGEs have noticeable pro-inflammatory and prooxidant  impacts9. Furthermore a positive 
association between AGEs intake and serum level of AGEs, visceral fat and insulin resistance has been detected, 
which suggests a casual role of dietary AGEs in metabolic syndrome independent from energy  balance10,11. 
When that AGE production binding to receptors AGEs (RAGE), AGEs trigger generation of reactive oxygen 
species (ROS) and initiate a downstream pro-inflammatory signaling cascade including activation of RAGE/
TLR4 (Toll-like receptors 4)-NF-κB-ROS  pathways12 and contribute to both obesity and related inflammatory 
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 diseases13. Since diet derived AGEs increase the risk of obesity and related inflammatory diseases, reduced intake 
of AGEs is thought to be beneficial, independently from the intake of a standard calorie restricted  diet7. Several 
studies have shown that consumption of low dietary AGEs is associated with reduced circulating and urinary 
levels of AGE markers and improved anthropometric, glycemic, cardio metabolic and inflammatory indices in 
individual with overweight and  obese14–17. However, the exact mechanism of action of AGEs in obesity-related 
complications remains unknown. Also there is no established recommendation surrounding the intake of foods 
with high amount of AGEs such as heat treated cereal or powdered milk which may be considered contributing 
to a healthy diet. Therefore, this meta-analysis was carried out to analyze the effects of diet-derived AGEs on 
obesity and related hormones, as well as to discuss the molecular mechanisms of action of these compounds on 
the development of chronic diseases.
Results
Search results. The flow diagram of the process of study selection is shown in Fig. 1. In total, we identified 
6469 through database searching and 2 studies identified through other sources. After excluding of duplicates, 
3444 papers remained for additional screening based on title and abstract. 3380 one studies were discarded leav-
ing after screening based on title and abstract. Finally, 64 potentially eligible studies for further evaluation that 
51 article excluded due to; non-RCT (n = 31), duration of intervention < 24 h (n = 5), no AGE diet (n = 6), full-
text not available (n = 3) and no outcome of interest (n = 6). Finally, 13 RCT studies included for this systematic 
review and meta-analysis.
Study characteristics. The detailed characteristics of all included studies are described in Table 1. Nine 
studies used parallel  design6,14,15,18–23 and four used cross-over  design16,17,24,25. The intervention duration varied 
from  216,17,24 to 48  weeks6. Four studies have investigated the effects of AGE diet in patients with  T2DM18–21, six 
studies in Obese or overweight  people6,14–17,24, two studies in healthy  individuals22,23 and one study in women 
with  PCOS25. Overall, ten RCTs reported changes in  BMI6,14,15,17,19,20,22–25, seven  weight6,14–18,21, three  WC6,14,15 , 
three  leptin6,18,23, and tree  adiponectin6,18,23, following AGE diet consumption.
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Figure 1.  Flow chart of study selection process.
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Risk of bias assessment. As shown in Table 2, six studies were assessed as unclear risk in random sequence 
generation, cause they did not explicitly mention the random sequence generation  methods14,18,20,21,23,24 and one 
as high  risk25. Two studies were assessed as low risk in allocation  concealment15,16 and one as high  risk25, while 
the other ten studies as unclear. There was one study which was double-blinded, thus considered as low risk of 
bias for blinding of participants and  personnel17. Four of the trials provided a clear description of blinding of 
outcome  assessment6,15–17. Six studies were clear on providing incomplete outcome data and then were consid-
ered as low risk of  bias6,14,16–19. Six studies were assessed as unclear risk of bias in selective  reporting17,20–24, and 
the other seven studies were assessed as low risk of bias. Except for one study that was considered as high risk in 
 quality25, the other twelve studies were considered as unclear risk of bias, cause we found at least one of their six 
key domains of quality as unclear.
Table 1.  Included randomized controlled trial study characteristics by population. WC; Waist circumference; 
BMI; Body mass index.
Study ID Study design Participants Sample size Intervention diet Control diet Duration dAGE content Outcomes






11 LAGE diet HAGE diet 2 weeks
HAGE = 14,090, 
LAGE = 3302 kU AGE/
day
BMI
Uribarri 2011 Parallel Type 2 diabetic patients
18 randomised, 
18 assessed: 12 
LAGE & 6 HAGE
LAGE diet HAGE diet 4 months
HAGE =  > 20, 









20 assessed LAGE diet HAGE diet 2 weeks








36 LAGE & 37 
HAGE diet
LAGE diet HAGE diet 4 weeks
HAGE = 24.6, 







m2) aged 30 to 55 
years
75 randomised, 
45 assessed: 15 
in the diet plus 
exercise group, 
14 in the exercise 
group, and 14 in 
the diet group
LAGE diet HAGE diet 12 weeks
HAGE = 13,284 + 4983, 
LAGE  = 13,019 + 4526 
kU AGE/day
BMI Weight WC







23 assessed LAGE diet HAGE diet 8 weeks
HAGE = 1869.6 ± 114.6, 
LAGE = 1869.6 ± 114.6 
kU AGE/day
BMI
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18.5 and 40 kg/ 
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in LAGE & 49 
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with normal lipid 
profile & renal 
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11 HAGE & 13 
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and normal renal 
function
11 for cross over 
and 13 for paral-
lel trials (6 in 
high and 7 in low 
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LAGE diet HAGE diet 6 weeks HAGE = 5 times higher than LAGE weight





11 HAGE & 13 
LAGE
LAGE diet HAGE diet 2 weeks HAGE = 3 times higher than LAGE BMI weight
Yacoub2017 Parallel Healthy adults aged 50–69 years
20 randomised, 
20 assessed: 10 in 
each group
LAGE diet HAGE diet 6 weeks
HAGE = 26.96 , 
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of 60
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LAGE & 6 HAGE
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HAGE =  > 15, 
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Meta‑analysis. Effects of low dietary AGEs on BMI. The quantitative analysis of value indicated a signifi-
cant reduction of BMI after consumption of the low AGE diets compared to the high AGE diets (WMD: − 0.3 kg/
m2; 95% CI: − 0.52, − 0.09, p = 0.005;  I2 = 55.8%) (Fig. 2). Our findings for the subgroup analyses showed that 
low AGE diets reduced BMI regardless of length of follow up. These analyses displayed that length of follow 
up ≥ 8 weeks (WMD: − 0.47 kg/m2, 95% CI: − 0.85, − 0.09) more effectively reduced BMI compared with length 
of follow up > 8 weeks. Also, the findings from the subgroup analyses showed that BMI levels were significantly 
reduced in patients with overweight or obese (WMD: − 0.41 kg/m2, 95% CI: − 0.72, − 0.11) (Supplemental Fig. 1).
Effects of low dietary AGEs on Weight. After intake of low AGE compared to high AGE diets, Pooled results 
from the random-effects model showed a significant decrease in Weight(WMD: − 0.83 kg; 95% CI: − 1.55, − 0.10, 
p = 0.026;  I2 = 67.0%) (Fig. 3). The duration of intervention was considered as a heterogeneity factor on overall 
effect size. When studies were categorized based on length of follow-up, the effect of intake of low AGE com-
pared to high AGE diets was more pronounced in subgroup with duration > 8 weeks (WMD: − 1.50 kg, 95% CI: 
− 2.12, − 0.88). In addition, low AGE diets were associated with a significant reduction in weight regardless of the 
participants’ with overweight or obese (WMD: − 0.84 kg, 95% CI: − 1.65, − 0.02) (Supplemental Fig. 2).
Effects of low dietary AGEs on waist circumference. Among the included studies, three clinical article examined 
WC. After pooling effect sizes, no significant difference between low and high AGE diets with regards to WC 
(WMD: − 0.81 cm; 95% CI: − 2.80, 1.18, p = 0.43;  I2 = 93.2%) (Fig. 4). Also, subgroup analysis for WC was not 
possible as there were no enough studies in each group.
Effects of low dietary AGEs on leptin and adiponectin. The pooled WMD of 3 effect sizes showed a significant 
decrease in leptin (WMD: − 19.85 ng/ml; 95% CI: − 29.88, − 9.82, p < 0.001;  I2 = 81.8%) (Fig. 5) and an increase in 
adiponectin levels (WMD: 5.50 µg/ml; 95% CI: 1.33, 9.67, p = 0.010;  I2 = 90.6%) (Fig. 6) after consumption of the 
low AGE diets compared to the high AGE diets. It was not possible to conduct subgroup analysis for leptin and 
adiponectin with regards to length of follow-up and health status, due to the low number of studies.
Meta‑regression results. We performed a meta‐regression analysis to examine the variation in treatment 
effect of low AGE diets based on duration of intervention and mean age of participants. The duration of inter-
vention did not demonstrate any significant changes in BMI (p = 0.07, coef: 0.445) and weight (p = 0.43, coef: 
0.321). Also, meta‐ regression analysis of mean age of intervention showed no significant effect on BMI (p = 0.86, 
coef: 0.630) and weight (p = 0.39, coef: 0.673) (supplemental Figs. 3, 4). Due to the limited number of studies on 
WC, leptin, and adiponectin, we could not perform the meta‐regression analysis.
Sensitivity analysis. We removed each trial from the analysis, step by step, in order to discover the impact 
of each single study on the combine effect size. We observed no significant effect of any individual study on the 
combine effect sizes of BMI and Weight (supplemental Fig. 5). Due to the limited number of studies on WC, 
leptin, and adiponectin, we could not perform the analysis.
Publication bias. A review of the funnel plots used to assess the publication bias is shown in Supplementary 
Fig. 6. Funnel plot showed no publication bias for BMI and Weight that were confirmed with Egger’s regression 
test (BMI: p = 0.53) and (weight: p = 0.45).














outcome data Selective reporting
Overall 
assessment of risk 
of bias
Harcourt 2011 Unclear Unclear Unclear Unclear Low Low Unclear
Uribarri 2011 Low Unclear Unclear Low Low Low Unclear
de Courten 2016 Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Mark 2014 Low Unclear Unclear Unclear Low Low Unclear
Macías-Cervantes 
2015 Low Unclear Low Low Low Unclear Unclear
Tantalaki 2014 Low Low Unclear Low Low Low Unclear
Di Pino 2016 Unclear Unclear Unclear Unclear Low Low Unclear
Vlassara 201(28) Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Cai 2004(13) Low Low Unclear Low Unclear Low Unclear
Vlassara 2002 Low Unclear Unclear Unclear Unclear Unclear Unclear
Baye 2017 Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Yacoub 2017 Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Uribarri 2014 High High Unclear Unclear Unclear Low High
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NOTE: Weights are from random effects analysis







































Figure 2.  Forest plot of randomized controlled trials investigating the effects of low dietary AGEs on BMI.
NOTE: Weights are from random effects analysis






























Figure 3.  Forest plot of randomized controlled trials investigating the effects of low dietary AGEs on weight.
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Discussion
This systematic review and meta-analysis was conducted to assess the effects of consumption of low dietary 
AGEs on obesity and its related hormone. Our findings regarding obesity indices showed that low dietary AGEs 
could reduce BMI and body weight but had no noticeable impact on waist circumference. Regarding obesity 
related hormones our results revealed a significant reduction in leptin and rise in adiponectin levels following 
consumption of low diet derived AGEs. These findings agree with the previous literature reporting that higher 
dietary consmption of AGEs was linked to increased body  weight26,27.The evidently high amounts of AGEs in the 
diet especially in heat processed foods might be considered as one of the major potential factors contributting 
NOTE: Weights are from random effects analysis


















Figure 4.  Forest plot of randomized controlled trials investigating the effects of low dietary AGEs on WC.
NOTE: Weights are from random effects analysis
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to energy over  intake26. In a randomized controlled clinical trial, consumption of ultraprocessed foods resulted 
in markedly excessive energy intake and weight gain in comparision with to an unprocessed diet which caused 
reduction in body  weight28. AGEs may be considered as important dietary compounds that can result in energy 
imbalance and subseqently increased body weight. However, the underlying mechanism by which higher AGEs 
content of diet may increase the risk of weight gain is not fully understood. Suggestive evidence obtained from 
experimental and human studies have demonstrated that higher dietary AGEs intake can induce or aggravate 
insulin  resistance16,29,30. A systemaic review conduced by Clarke and colleagues demonstrated that insulin sensi-
tivity was improved following intake of low dietary AGEs in healthy individuals and patients with type 2 diabetes 
mellitus. However no change in fasting glucose and HbA1c was  observed31.
High-normal insulin levels appear to prevent lipolysis and stimulate lipogenesis in  adipocytes32. Also an 
association between AGEs, insulin resistance, and weight gain has been reported in an in vivo study in Dros-
ophila where increased methylglyoxal stimulated insulin resistance and weight  gain30. It seems that hypothalamic 
inflammation is another pathway whereby higher dietary AGEs intake can increase weight. In an animal study 
over intake of fat and sugar stimulated hypothalamic inflammatory  responses33. In hypothalamic inflammatory 
state, the signaling pathway of insulin and leptin is impaired which can lead to an adaptive increase of food 
consumption relative to energy expenditure that advocates weight  gain34. However in Harcourt’s study, body 
weight and BMI were not significantly changed after a 2 weeks either isoenergetic low or high dietary AGEs. 
Matching of energy intake and the short duration of the intervention might explain the null effects on BMI and 
body  weight24. In case of waist circumferences, although the results of two  studies14,15 showed beneficial effects 
of GAEs on WC, analysis the results of all  studies6,14,15 showed no overall significant effects. The number of stud-
ied assessing the effects of low dietary AGEs on WC was too small. Therefore non-significant effects observed 
in our analysis might be related to this issue. The duration of intervention is an important factor to obtain real 
conclusion regarding the effects of nutritional intervention on health  outcomes7. The length of interventions 
varied among studies included in this meta-analysis and the results of subgroup analysis revealed that reduc-
tion effects of low AGE diets on body weight and BMI were more pronounced in groups with length of follow 
up ≥ 8 weeks. Also BMI were significantly reduced in individuals with overweight or obese after intake of a low 
AGEs diet. Overweight and obesity are considered as the two main risk factors for the development of inflam-
matory process and insulin  resistance35,36. Several Studies have demonstrated that consumption of low amount 
of dietary AGEs was associated with improved insulin resistance, reduced inflammatory markers and oxidative 
stress in overweight  individuals18,37. Therefore the observed reduction effects of low AGEs diet on BMI might 
be attributed to its beneficial impacts on inflammation and insulin resistance which is more noticeable in over-
weight and obesity. However the results of this meta-analysis revealed that the reduction impacts of low dietary 
AGEs on body weigh were not significantly different between weight subgroups. This finding may be due to 
the variation in methodology of the studies included in subgroup analysis, differences in the type of prescribed 
diet or prepared meals in each study and the length of follow up. Regarding adiponectin and leptin, our finding 
showed that a diet with low AGEs content could significantly increase adiponectin and decrease leptin levels, two 
important markers of insulin resistance, suggesting that diet derived AGEs also have effects on insulin sensitive 
 tissues38–41. These results are consistent with previous meta-analysis findings showing the same improvement 
effects of the low AGEs diet on adiponectin and leptin  levels42. Another meta-analysis conducted by Kellow 
NOTE: Weights are from random effects analysis
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et al., has also showed that consumption of a low AGEs diet significantly decreased TNFα and 8-isoprostanes 
in healthy  individuals11. SIRT1 which is a gene encoding protein belonging to the sirtuin family, is considered 
as a major regulator of inflammatory processes and also adiponectin  levels23. Several studies have reported the 
suppression impacts of oxidant AGEs on gene expression of  SIRT118,23. Therefore it is thought that improving 
impacts of the AGE-restricted diet on insulin resistance be related to its reduction impacts on inflammatory 
processes, oxidative stress and leptin levels along with an increased in adiponectin and sirtuin-143,44. Also, AGEs 
storage in adipose tissue by binding to receptors AGEs (RAGE unregulated the production of adipokines, such 
as adiponectin, leptin, monocyte chemotherapy protein (MCP-1), and plasminogen activator inhibitor type 
I (PAI-1), which Recent studies have shown that these compound poses a potential risk for cancer and other 
immune-related diseases through a variety of factors, such as suppressing the immune system and disrupting 
the regulation of monocytes, basophil, T lymphocytes, and NK  cells45,46. AGEs-derived adipokines also appear 
to increase the production of reactive oxygen species and initiate anti-inflammatory signaling, which in turn 
further impairs the immune  system12.
This systematic review and meta-analysis has a number of strengths. In this study, we performed a systematic 
review and meta-analysis on a wide range of obesity related factors including values of BMI, WC, Weight, leptin, 
and adiponectin that have not been reported before. Meta-analysis was also conducted according to subgroups 
to further detect the results of each risk factor. In addition, publication bias was checked for all of the obesity 
related factors. Despite the above strengths, some limitations should be considered when interpreting the results. 
Approximately half of the studies included in this review had poor methodological quality and length of inter-
vention < 24 h. Therefore, we were unable to conduct a meta-analysis for these studies. In addition, differences 
in characteristic of prescribed diets or meals such as baseline dietary AGE levels, reliability of methods used for 
food preparation amongst studies must also be taken into account a confounding factor. Also, in most studies, 
the food was not prepared for the participants (a small number of them, but most of them only provided dietary 
advice on how to reduce the AGEs in their usual diet), This problem may cause a not match in the total energy 
received between the groups and the results may be at risk of bias.
In conclusion, our systematic reviews and meta-analyses have shown a significant decrease in BMI, weight, 
and leptin and an increase in adiponectin levels after consumption of the low AGE diets compared to the high 
AGE diets. Also, the effect of intake of low AGE compared to high AGE diets was more pronounced in subgroup 
with duration > 8 weeks for the BMI and weight. According to our study, low AGE diet can be effective in reduc-
ing the incidence of obesity and chronic diseases associated with high consumption of dietary AGEs. Therefore, 
reducing the consumption of processed foods that have high AGE content and changing food preparation 
methods are good strategies to promote health. Further prospective studies should be conducted in this regard.
Methods
Protocol. The present systematic review and meta-analysis was performed based on the principals of the 
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)  statement47.
Search strategy. A systematic literature search was conducted in four electronic databases: Ovid MED-
LINE, ISI Web of Science, Scopus, the Cochrane Central Register of Controlled Trials, and, Embase up to Octo-
ber, 2019. The following MeSH and text keywords were applied to identify relevant articles: (“advanced glycation 
end products” OR “glycation end products, advanced” OR “maillard reaction” OR “dietary advanced glycation 
end products” OR “circulating advanced glycation end products”) AND (obesity OR overweight OR adiponec-
tin OR leptin) NOT review*. No language or date restrictions were imposed in the search. The detailed search 
strategy is provided in the Supplementary Appendix. To find relevant studies, 2 authors (Mh, S and AL) indepen-
dently screened the titles, abstracts, and full texts of the retrieved articles. The references of the included reviews 
were also hand-searched to identify further related papers. The study protocol was previously registered with the 
International prospective register of systematic reviews (PROSPERO) database as CRD42020203734.
Study selection. All adult clinical trials examining the impacts of low dietary intake of AGEs on obesity 
and related hormone were included. We excluded studies if they were (1) conducted on children; (2) assessed 
single food item rather than whole diet; (3) lasted < 24 h; 4) not reported sufficient data on targeted outcomes. 
Reviews, comments, abstracts, letters, case reports and unpublished articles were also excluded from the study.
Data extraction. All studies were stored and managed by Endnote. After reading the selected articles all 
data were extracted and their integrity and reliability were assessed by two independent reviewers (Mh, S and SF) 
which were double checked by other authors (FSH and AL). Differences in decisions about the selected studies 
were resolved by consensus. Extracted information regarding each included study was as follows: title, author 
name(s), year of study publication, study aim, population’s characteristics, sample size, study design, type of 
intervention (low/high AGE consumption), duration of the study duration, and, means and standard deviations 
of weight, BMI, WC, leptin, and adiponectin levels at baseline, post treatment and/or changes between baseline 
and post treatment. . Data regarding obesity related hormones and anthropometric indices were also extracted. 
The detailed characteristics of all included studies are described in Table 1.
Assessment of risk of bias. The Cochrane Risk of Bias Tool for Randomized Controlled  Trials48 was used 
by two authors to identify potential risks of bias. The quality assessment tool encompasses the following items: 
adequacy of random sequence generation, allocation concealment, blinding, the detection of incomplete out-
come data as well as selective outcome reporting, and other potential sources of bias. Based on the recommen-
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dations of the Cochrane Handbook, judgment of each domain was recorded as “Low”, “High”, or “Unclear” risk 
of bias. Any disagreement in the data extraction and the risk of bias assessment was solved by a third reviewer.
Data analyses. All studies were reviewed based on their main characteristic and results concerning obesity 
related factors. The primary outcome was Body weight, BMI and waist circumference. The serum levels of leptin 
and adiponectin were considered as secondary outcomes of interest.
Data synthesis and statistical analysis. Data were combined, if there were ≥ 3 trials within a single grouping 
using the generic inverse variance approach with random effects model and reported as weighted mean dif-
ferences (WMDs). The random effects model and reported as weighted mean differences (WMDs) were used 
because included studies were performed on different populations. The statistical analysis was done using Rev-
Man V.5.3 software and STATA version 12.0 (Stata Corp, College Station, TX, USA). If data were expressed in 
a different format, standard calculations were executed to obtain the mean and  SDs48,49. For instance, if the SDs 
of the change were not stated in the trials, we derived it using the following formula: SD changes = square root 
[(SD baseline 2 + SD final 2) − (2 × R × SD baseline × SD final)]. Also, for trials that only reported standard error 
of the mean (SEM), SDs were obtained using the following formula: SD = SEM × √n, where “n” is the number 
of subjects in each group. Heterogeneity was examined using the I-squared  (I2) statistic, in which source of 
heterogeneity was determined if the  I2 value was > 50%, or if there in the case of inconsistency across RCTs 
 data50. In order to identify potential sources of heterogeneity, a pre-defined subgroup analysis based on amount 
of low AGE, duration of intervention, and health status of subjects was performed. Meta‐regression was used 
to determine effect of duration of intervention and mean age of participants on outcomes. A sensitivity analysis 
was applied to assess the contribution of each study to the overall mean difference. We assessed the presence of 
publication bias using the formal Egger’s  test51.
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